Multivariate optoacoustic sensor for longitudinal diabetes monitoring
MOSAIC aims to develop a portable, non-invasive optoacoustic sensor powered by explainable AI to monitor diabetes, enhancing early detection and treatment while reducing healthcare costs.
Projectdetails
Introduction
MOSAIC will radically miniaturize non-invasive optoacoustic technology and make it portable by coupling optoacoustic sensing to novel explainable artificial Intelligence (xAI) to monitor a major health threat in the 21st century: Diabetes Mellitus.
Technology Overview
MOSAIC is based on recent advances in optoelectronic miniaturization and uses the skin as a window to dermal microvasculature. It resolves a large number of biomarkers associated with diabetes. The technology is offered as a fast sensor that is inexpensive and reliable, entirely non-invasive and portable, and supported by elaborate quality control monitoring so that it can be employed for long-term patient monitoring.
Predictive Power
Based on proof-of-concept human measurements, xAI will further independently characterize the predictive power of each biomarker and other clinical measurements to improve accuracy for continuous grading of disease status.
Impact
With 537 million diabetics and a large at-risk population, MOSAIC potentially relates to 2 billion people and aims to reach more individuals than is practical to screen in medical facilities. It offers early diabetes detection for early interventions, as well as treatment monitoring, improving life expectancy, quality of life, and reducing healthcare costs.
Innovation
The sensor addresses five barriers to successful adoption:
- It is non-invasive.
- It senses highly multiplexed biomarkers.
- It can be easily integrated into daily routine.
- It uses fully automated data analytics.
Collaboration
MOSAIC synergistically integrates three teams on sensor developments, data analytics, and xAI, one preclinical and one clinical team for sensor validation in mice and humans, respectively, and an SME for exploitation.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.997.921 |
Totale projectbegroting | € 2.997.921 |
Tijdlijn
Startdatum | 1-2-2025 |
Einddatum | 31-1-2029 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBHpenvoerder
- UNIVERSIDAD AUTONOMA DE MADRID
- ARISTOTELIO PANEPISTIMIO THESSALONIKIS
- SPEAR UG (HAFTUNGSBESCHRANKT)
- MEDIZINISCHE UNIVERSITAT GRAZ
- UNIVERSITA DEGLI STUDI DI BARI ALDO MORO
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Mid-infrared Wearable for Non-invasive biomarker monitoringThe project aims to develop a wearable device using a miniature Mid-Infrared spectrometer for non-invasive biomarker detection in metabolic syndrome, enhancing early diagnosis and management. | EIC Pathfinder | € 3.991.297 | 2024 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
integrated nano-photonic OMICs bio-SENSor for lung cancerOMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment. | EIC Pathfinder | € 2.372.318 | 2024 | Details |
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technologyDISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI. | EIC Pathfinder | € 3.018.312 | 2022 | Details |
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared careI(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care. | EIC Pathfinder | € 3.454.613 | 2024 | Details |
Mid-infrared Wearable for Non-invasive biomarker monitoring
The project aims to develop a wearable device using a miniature Mid-Infrared spectrometer for non-invasive biomarker detection in metabolic syndrome, enhancing early diagnosis and management.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
integrated nano-photonic OMICs bio-SENSor for lung cancer
OMICSENS aims to develop a novel nano-photonic omics bio-sensor for real-time detection of TKI resistance in NSCLC, enhancing prognosis and paving the way for personalized cancer treatment.
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology
DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.
I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care
I(eye)-Screen aims to develop an AI-based system for early detection and monitoring of age-related macular degeneration, enhancing accessibility and health equity in vision care.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Metal-Organic-Framework Kinetic Array for Diabetes DetectionThis project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis. | ERC Proof of... | € 150.000 | 2024 | Details |
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensingGLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications. | EIC Transition | € 2.194.210 | 2022 | Details |
From Research Optoacoustic Novelty To Imaging Established in Routine diagnosticsFRONTIER aims to translate the innovative MSOT technology into routine clinical imaging, enhancing disease diagnosis and treatment monitoring for clinicians globally. | EIC Accelerator | € 2.451.121 | 2022 | Details |
Intelligent Optoacoustic Radiomics via Synergistic Integration of System Models and Medical KnowledgeEchoLux aims to revolutionize radiomics by integrating imaging hardware, medical knowledge, and Bayesian reasoning for explainable diagnostics in optoacoustic imaging of peripheral neuropathy. | ERC Starting... | € 1.499.976 | 2022 | Details |
AFIDIHet project ontwikkelt een betaalbare, minimaal invasieve CGM-sensor voor diabetespatiënten, die data veilig beheert en artsen toegang geeft, ter verbetering van zorg en vroegtijdige detectie van vaatlijden. | Mkb-innovati... | € 344.962 | 2023 | Details |
Metal-Organic-Framework Kinetic Array for Diabetes Detection
This project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis.
Next generation in-blood glucose monitoring using non-invasive optoacoustic sensing
GLUMON aims to develop a next-gen non-invasive optoacoustic sensor for continuous blood glucose monitoring, enhancing diabetes care and exploring precision nutrition applications.
From Research Optoacoustic Novelty To Imaging Established in Routine diagnostics
FRONTIER aims to translate the innovative MSOT technology into routine clinical imaging, enhancing disease diagnosis and treatment monitoring for clinicians globally.
Intelligent Optoacoustic Radiomics via Synergistic Integration of System Models and Medical Knowledge
EchoLux aims to revolutionize radiomics by integrating imaging hardware, medical knowledge, and Bayesian reasoning for explainable diagnostics in optoacoustic imaging of peripheral neuropathy.
AFIDI
Het project ontwikkelt een betaalbare, minimaal invasieve CGM-sensor voor diabetespatiënten, die data veilig beheert en artsen toegang geeft, ter verbetering van zorg en vroegtijdige detectie van vaatlijden.